By contrast and as observed in ovarian cancer, a subset of patients derived clinical benefit of this combination irrespective of BRCA1/2-gene or PD-L1 status [289], again stressing the need to identify specific biomarkers of response for such combinations. The gene discussed is BRCA1; the disease is ovarian carcinoma.